ANTI-CD22 90y-epratuzumab tetraxetan combined with anti-cd20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-hodgkin lymphoma

Thomas E. Witzig, Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, David M. Goldenberg

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabeled anti-CD20 antibody. We instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. We evaluated the anti-CD22 90Y-epratuzumab tetraxetan with the anti-CD20 veltuzumab in patients with aggressive lymphoma in whom at least one prior standard treatment had failed, but who had not undergone stem cell transplantation. Eighteen patients (median age 73 years, median of 3 prior treatments) received 200 mg/m2 veltuzumab once-weekly for 4 weeks, with 90Y-epratuzumab tetraxetan at planned doses in weeks 3 and 4, and 111In-epratuzumab tetraxetan in week 2 for imaging and dosimetry. Veltuzumab effectively lowered levels of B cells in the blood prior to the radioimmunotherapy doses. No significant immunogenicity or change in pharmacokinetics of either agent occurred in combination. 111In imaging showed tumor targeting with acceptable radiation dosimetry to normal organs. For 90Y-epratuzumab tetraxetan, transient myelosuppression was dose-limiting with 6 mCi/m2 (222 MBq/m2) × 2 being the maximal tolerated dose. Of 17 assessable patients, nine (53%) had objective responses according to the 2007 revised treatment response criteria, including three (18%) complete responses (2 relapsing after 11 and 13 months, 1 continuing to be clinically disease-free at 19 months), and six (35%) partial responses (1 relapsing after 14 months, 5 at 3-7 months). Responses occurred in patients with different lymphoma histologies, treated at different 90Y dose levels, and with a predicted risk of poor outcome, most importantly including five of the six patients treated with the maximal tolerated dose (2 of whom achieved durable complete responses). In conclusion, the combination of 90Y-epratuzumab tetraxetan and veltuzumab was well-tolerated with encouraging therapeutic activity in this difficult-to-treat population.

Original languageEnglish (US)
Pages (from-to)1738-1745
Number of pages8
JournalHaematologica
Volume99
Issue number11
DOIs
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'ANTI-CD22 <sup>90</sup>y-epratuzumab tetraxetan combined with anti-cd20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this